Hallmarks of Cancer - get fired up about the latest research

If you are unable to view this message correctly, [click here]( [Cell Symposia: Hallmarks of Cancer ]( Dear colleague, Take a look at what some of our [Cell Symposia: Hallmarks of Cancer]( speakers have published recently and chat with them about their work in San Diego, USA. Keynote speakers Carl June, University of Pennsylvania, Philadelphia, USA [The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function]( Jennifer Wargo, The University of Texas MD Anderson Cancer Center, Houston, USA [Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade]( Speakers Timothy Chan, Cleveland Clinic, Cleveland, USA [Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy]( Lisa Coussens, Oregon Health & Science University, USA [Safety and efficacy of pembrolizumab in combination with acalabrutinib in advanced head and neck squamous cell carcinoma: Phase 2 proof-of-concept study]( Maximilian Diehn, Stanford University, Stanford, USA [Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA]( Philip Greenberg, Fred Hutchinson Cancer Research Center, Seattle, USA [Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy]( John Haanen, The Netherlands Cancer Institute, Amsterdam, Netherlands [Discontinuation of anti-PD-1 monotherapy in advanced melanoma—Outcomes of daily clinical practice]( Han Liang, The University of Texas MD Anderson Cancer Center, Houston, USA [A functional genomic approach to actionable gene fusions for precision oncology]( Howard Hang, Scripps Research, San Diego, USA [Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy]( Rob Knight, University of California at San Diego, San Diego, USA [Assessment of the microbiome during bacteriophage therapy in combination with systemic antibiotics to treat a case of staphylococcal device infection]( Miriam Merad, Icahn School of Medicine at Mount Sinai in New York City, New York, USA [Single-cell analysis of human non-small-cell lung cancer lesions refines tumor classification and patient stratification]( Antoni Ribas, University of California at Los Angeles, Los Angeles, USA [Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma]( Stanley Riddell, Fred Hutchinson Cancer Research Center, Seattle, USA [Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function]( Andrea Schietinger, Memorial Sloan Kettering Caner Center, USA [TOX is a critical regulator of tumour-specific T cell differentiation]( Ravid Straussman, Weizmann Institute of Science, Rehovot, Israel [Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer]( Charles Swanton, The Francis Crick Institute, London, UK [Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition]( Suzanne Topalian, Johns Hopkins Medicine, Baltimore, USA [The genetic evolution of treatment-resistant cutaneous, acral, and uveal melanomas]( David Tuveson, Cold Spring Harbor Laboratory, New York, USA [Inhibition of hedgehog signaling alters fibroblast composition in pancreatic cancer]( Karin de Visser, The Netherlands Cancer Institute, Amsterdam, Netherlands [Tumor-educated Tregs drive organ-specific metastasis in breast cancer by impairing NK cells in the lymph node niche]( Catherine Wu, Dana-Farber Cancer Institute, Boston, USA [Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer]( Laurence Zitvogel, Institut Gustave Roussy, Villejuif, France [Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer]( Submit your own research for presentation and join us and our speakers this October in San Diego, USA. Deadline for abstract submission is June 24, 2022. [SUBMIT YOUR ABSTRACT HERE]( Yours sincerely, Organizers: [Steve Mao]( Editor-in-Chief, Cancer Cell [Yang Yang]( Scientific Editor, Cell Abstract submission deadline June 24, 2022 [Submit your abstract here]( Supporting publications [Trends in cancer]( [Cancer Cell]( [Cell]( [Cell Reports ]( [iScience]( [Trends in Molecular Medicine]( Family Support Awards [Elsevier]( Invitations to Cell Symposia - Offers & Invitations is a communication type sent to you by Cell Press. [Unsubscribe from this communication type.]( [Change your marketing email preferences]( on the Cell Press Preference Center Copyright © 2022 Elsevier Limited All rights reserved. | [Elsevier Privacy Policy]( Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB UK